Michael Sadick
About Michael Sadick
Michael Sadick serves as the Senior Director of CMC Analytical Development at Precision BioSciences, Inc., bringing over 35 years of experience in the biopharmaceutical industry. He has a strong background in analytical development, cell-based assays, and regulatory collaboration, having previously held positions at notable companies such as Catalent Pharma Solutions, Eli Lilly, and Genentech.
Work at Precision BioSciences
Michael Sadick serves as the Senior Director of CMC Analytical Development at Precision BioSciences, Inc. since 2020. In this role, he oversees analytical development processes and collaborates with various teams to ensure compliance with industry standards. His responsibilities include the development, pre-validation, and validation of cell-based assays and other analytical methodologies. He has been instrumental in aligning analytical strategies with regulatory requirements and quality assurance protocols.
Education and Expertise
Michael Sadick holds a Ph.D. in Immunology/Immunoparasitology from the University of Washington, where he studied from 1981 to 1985. He also earned a Bachelor of Arts in Biology from The Johns Hopkins University between 1975 and 1979. His academic background provides a solid foundation for his extensive expertise in cellular biology, immunology, molecular biology, and biochemistry, which spans over 35 years in the biopharmaceutical industry.
Background
Michael Sadick has a diverse professional background with significant roles in various organizations. He worked at Genentech as a Senior Scientist for ten years and served as a Research Advisor at Eli Lilly for six years. His earlier experience includes positions at UCSF Medical Center as a Research Faculty and Post-Doc. Prior to his current role, he was a Principal Scientist at Catalent Pharma Solutions, where he contributed to bioassay development and analytical methodologies.
Achievements
Throughout his career, Michael Sadick has led numerous initiatives in analytical and CMC teams within the biopharmaceutical sector. He has actively participated in establishing industry guidelines for relative potency assay approaches. His work involves collaboration with subject matter experts across various disciplines, including regulatory and quality assurance, to enhance the development and validation of analytical processes.